Alex Knapp is a senior editor at Forbes covering healthcare, science, and cutting edge technology who joined Forbes in 2011. He's written dozens of profiles of entrepreneurs across a variety of fields and done deep dives into technological trends from superconductors to space travel to pharmaceuticals.
Despite supply shortages, the drugs by the two companies saw their sales surge in the first quarter of the year, and competitors are still trying to catch up.t’s not often that a class of chemical becomes a household name, but glucagon-like peptide-1, aka GLP-1 , has achieved that status.
Jørgensen said he’s not too concerned about the competition yet. By the time a company gets to late-stage clinical trials, “you’re already too late,” he said. “It takes several years to build the kind of capacity you’re dealing with here, so it’s a daunting task to get it all in place.” Both companies are also looking to refine and develop what they hope are new and better versions. Lilly has new obesity drugs in its clinical development pipeline, including a monoclonal antibody treatment for obesity, as well as another potential new treatment that’s a different class of drug than GLP-1s but behaves similarly.with biotech company Metaphore to develop two new therapeutics in a deal potentially worth up to $600 million.
Novo Nordisk Ozempic Wegovy Mounjaro Zepbound Obesity Glp-1 Peptide Pharmaceutical
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
From Pharma's Factories Direct to YouWhy Eli Lilly's plan to disrupt the traditional doctor-patient relationship makes us nervous.
Read more »
Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentumThe Food and Drug Administration said supplies of Zepbound and Mounjaro are expected to be limited through the second quarter, for all but one dosage.
Read more »
Biden Wants To Take Your CarSteve Forbes is Chairman and Editor-in-Chief of Forbes Media.
Read more »
President Biden’s Latest Attack On The Economy: Smother The InternetSteve Forbes is Chairman and Editor-in-Chief of Forbes Media.
Read more »
Buffett's 2024 Investment Wisdom: Psychology Matters As Much As FinancialsI am the editor of three Forbes investment newsletters: Forbes Dividend Investor, Forbes Billionaire Investor and covered call writing advisory service, Forbes Premium Income Report. Prior to joining Forbes in 2001, I was a producer and reporter at CNN Financial News, focusing on stories about entrepreneurship.
Read more »
Why protesters in Georgia are opposed to a 'foreign agents' law and why it mattersMore than 50,000 people took to the streets of the capital city Tbilisi over the weekend to protest against proposed legislation that critics say is modeled on a Russian law used to crush dissent.
Read more »